SCHEMBL2534284

SCHEMBL2534284

O=C(O)c1cccc(-c2cccc3ccccc23)c1O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A1 P22736 1/20 0.63
NR4A2 P43354 1/20 0.63
NR4A3 Q92570 1/20 0.63
LDHA P00338 1/20 0.62
HNF4A P41235 1/20 0.62
MCL1 Q07820 1/20 0.58
ACMSD Q8TDX5 1/20 0.58
CDC25B P30305 2/20 0.56
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
KDM4E B2RXH2 2/20 0.53
ALDH1A1 P00352 2/20 0.53
HPGD P15428 2/20 0.53
HSD17B10 Q99714 2/20 0.52
WDR5 P61964 1/20 0.50
SOS1 Q07889 1/20 0.49
ALB P02768 1/20 0.47
MMP2 P08253 1/20 0.47
GFER P55789 1/20 0.47
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1641502 0.87 NR4A1 (0.70) NR4A1NR4A2NR4A3LDHAHNF4A
Ammonia Solution, Strong SCHEMBL11705221 0.85 NR4A1 (0.68) NR4A1NR4A2NR4A3LDHAMCL1
SCHEMBL5678745 0.84 HNF4A (0.76) NR4A1NR4A2NR4A3LDHAHNF4A
SCHEMBL28323302 0.84 KDM4E (0.50) NR4A1NR4A2NR4A3LDHAHNF4A
SCHEMBL6555236 0.84 NR4A1 (0.66) NR4A1NR4A2NR4A3LDHAHNF4A
SCHEMBL8031425 0.83 HNF4A (0.74) HNF4AKDM4EALDH1A1HPGDHSD17B10
SCHEMBL10948911 0.82 HNF4A (0.73) LDHAHNF4AKMT2AKDM4EALDH1A1
SCHEMBL13045627 0.81 NR4A1 (0.62) NR4A1NR4A2NR4A3LDHAMCL1
SCHEMBL28053504 0.81 HNF4A (0.61) NR4A1NR4A2NR4A3LDHAHNF4A
SCHEMBL5491008 0.81 DEGS1 (0.60) MEN1KMT2AKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2822532-B1 AQUEOUS POLYURETHANE DISPERSION IN THE TREATMENT OF ACNE COVESTRO DEUTSCHLAND AG (DE) 2018-09-19 EP claimed
EP-1261347-B1 THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING PERIODONTITIS WITH ANTIINFLAMATORY COMPOUNDS UNIV RUTGERS (US) 2009-09-30 EP claimed
EP-1617816-B1 NANOPARTICULATE MELOXICAN FORMULATIONS ELAN PHARMA INT LTD (IE) 2009-05-13 EP claimed
EP-1480624-B1 PHARMACEUTICAL TABLET PHARMACIA CORP (US) 2006-11-29 EP claimed
EP-1471890-B1 PHARMACEUTICAL DOSAGE FORM FOR MUCOSAL DELIVERY PHARMACIA CORP (US) 2006-09-27 EP claimed
EP-1608407-B1 DISPERSIBLE FORMULATION OF AN ANTI-INFLAMMATORY AGENT PHARMACIA CORP (US) 2006-08-30 EP claimed
US-20250162979-A1 P-DIPHENYL COMPOUND DERIVATIVE MIXTURE AND METHOD OF PRODUCING THE SAME HODOGAYA CHEMICAL CO., LTD. (JP) 2025-05-22 US disclosed
CN-115605254-A Balloon catheter with precise drug elution capability 巴德股份有限公司(US) 2023-01-13 CN disclosed
US-20220324791-A1 P-DIPHENYL COMPOUND DERIVATIVE MIXTURE AND METHOD OF PRODUCING THE SAME HODOGAYA CHEMICAL CO., LTD. (JP) 2022-10-13 US disclosed
EP-2394980-B1 AROMATIC AMINO COMPOUND MANUFACTURING METHOD HODOGAYA CHEMICAL CO LTD (JP) 2016-12-21 EP disclosed
US-9238624-B2 Method of producing aromatic amino compounds HODOGAYA CHEMICAL CO., LTD. (JP) 2016-01-19 US disclosed
US-20140163232-A1 METHOD OF PRODUCING AROMATIC AMINO COMPOUNDS HODOGAYA CHEMICAL CO., LTD. (JP) 2014-06-12 US disclosed
US-8735626-B2 Method of producing aromatic amino compounds HODOGAYA CHEMICAL CO., LTD. (JP) 2014-05-27 US disclosed
WO-1994010143-A1 NEW SUBSTITUTED AZETIDINONES AS ANTI-INFLAMMATORY AND ANTIDEGENERATIVE AGENTS MERCK & CO., INC. (US) 1994-05-11 WO disclosed
WO-1994010142-A1 NEW SUBSTITUTED AZETIDINONES AS ANTI-INFLAMMATORY AND ANTIDEGENERATIVE AGENTS MERCK & CO., INC. (US) 1994-05-11 WO disclosed
EP-0595557-A1 New substituted azetidinones as anti-inflammatory and antidegenerative agents MERCK & CO. INC. (US) 1994-05-04 EP disclosed
US-5229381-A Inhibitors of leukocyte enzyme elastase MERCK & CO., INC. (US) 1993-07-20 US disclosed
EP-0525973-A2 Substituted azetidinones as anti-inflammatory and antidegenerative agents MERCK & CO. INC. (US) 1993-02-03 EP disclosed
WO-1993000332-A1 SUBSTITUTED AZETIDINONES AS ANTI-INFLAMMATORY AND ANTIDEGENERATIVE AGENTS MERCK & CO., INC. (US) 1993-01-07 WO disclosed
EP-0481671-A1 New substituted azetidinones as anti-inflammatory and antidegenerative agents MERCK & CO. INC. (US) 1992-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324791-A1 P-DIPHENYL COMPOUND DERIVATIVE MIXTURE AND METHOD OF PRODUCING THE SAME DDT, CYP2D6, CYP3A4 NR4A1 1328/4885NR4A2 1398/4885NR4A3 1706/4885
US-20140163232-A1 METHOD OF PRODUCING AROMATIC AMINO COMPOUNDS DDC, AOC2, AOC3 NR4A1 3217/4885NR4A2 3019/4885NR4A3 2757/4885
US-20250162979-A1 P-DIPHENYL COMPOUND DERIVATIVE MIXTURE AND METHOD OF PRODUCING THE SAME DDT, CYP2D6, CYP3A4 NR4A1 1328/4885NR4A2 1398/4885NR4A3 1706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.